Post-Authorization Safety Study (PASS) of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK2340272A) in the United Kingdom (UK)
Post-Authorization Safety Study (PASS) of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK2340272A) in the United Kingdom (UK)
The focus of this study is to assess the safety of GSK's H1N1 vaccine in real life conditions as soon as the vaccine is used, in a mass vaccination programme, and with a system for rapid generation, communication and evaluation of safety data.
This study is a commitment to the European Medicines Agency (EMEA), as part of GlaxoSmithKline Biologicals' (GSK Biologicals') risk management plan for pandemic influenza vaccination.
Collaborator: Medicines and Healthcare products Regulatory Agency
Inclusion Criteria:
Exclusion Criteria:
Balham, London, SW12 8WU, United Kingdom
Bath, Avon, BA2 4JT, United Kingdom
Boughton, King's Lynn, PE33 9AG, United Kingdom
Bristol, Avon, BS13 8LD, United Kingdom
Comberton,Cambridge, CB23 7DY, United Kingdom
Devon, EX9 6LS, United Kingdom
Escrick, York, YO19 6LE, United Kingdom
Essex, CO3 4LN, United Kingdom
Hanworth, Feltham, TW13 6HD, United Kingdom
Harwood, Bolton, BL2 3HQ, United Kingdom
Hertfordshire, SG6 4TS, United Kingdom
High Kelling,Holt,Norfolk, NR25 6QA, United Kingdom
Hoyland, Barnsley, S74 9AF, United Kingdom
Kent, Sevenoaks, TN13 3NT, United Kingdom
Kettering,Kettering, NN14 1SN, United Kingdom
Kippax,Leeds, LS25 7JN, United Kingdom
Lambeth, London, SW16 5LS, United Kingdom
Lancashire, BL1 6AP, United Kingdom
Mossley, Ashton Under Lyne, OL5 0HE, United Kingdom
Orton Goldhay, Peterborough, PE2 5GP, United Kingdom
Oxfordshire, OX12 9BN, United Kingdom
Paiginton, Devon, TQ3 3TB, United Kingdom
Radstock, Bath, BA3 2UH, United Kingdom
Somerset, TA18 8BX, United Kingdom
Thornbury, Bristol, BS35 1DP, United Kingdom
Westhoughton, Bolton, BL5 3UB, United Kingdom
Wiltshire, SN10 4AQ, United Kingdom
Windemere,Cumbria, LA23 2EG, United Kingdom